Low-Calorie Diet Plus Exercise Reversed Type 2 Diabetes in 54% of Young Adults
A randomized trial found an 800-calorie diet combined with supervised exercise put early-onset type 2 diabetes into remission in over half of participants.
Summary
The RESET for Remission trial tested whether a very low-calorie meal-replacement diet paired with structured exercise could reverse type 2 diabetes in adults under 45 without medication. Among 96 participants, 54% achieved remission at 24 weeks — defined as HbA1c below 6.5% without glucose-lowering drugs — compared to just 4% in the usual care group. The 12-week intensive phase involved an 800–900 calorie daily diet and three exercise sessions per week, followed by a 12-week maintenance phase. Notably, the intervention produced greater reductions in visceral and liver fat than tirzepatide, despite less total weight loss. Remarkably, 90% of participants completed the trial, suggesting the demanding protocol is feasible.
Detailed Summary
Early-onset type 2 diabetes — diagnosed before age 45 — is an aggressive form of the disease associated with rapid complications that can derail careers, relationships, and family plans. The RESET for Remission trial asked whether intensive lifestyle intervention could reverse it entirely, without medication.
The randomized trial enrolled 96 adults aged 18–45 (average age 38) with diabetes diagnosed within the prior six years. Half received an 800–900 calorie daily meal-replacement diet combined with twice-weekly supervised aerobic and resistance exercise plus one independent session per week for 12 weeks, followed by a 12-week structured maintenance phase. The control group received routine clinical care.
Results were striking: 54% of the intervention group achieved remission — HbA1c below 6.5% without glucose-lowering medication for at least 12 weeks — versus just 4% in the control group (adjusted OR 21.6). Remission rates held consistent across sex, ethnicity, and country subgroups. Most participants stuck with the demanding protocol; 90% completed their final assessment.
A key metabolic insight emerged when researchers compared outcomes with tirzepatide data from SURPASS-3. Although total weight loss was lower (16.5 lb at 24 weeks vs. 28.4 lb at 52 weeks), the lifestyle intervention produced greater reductions in visceral and liver fat — both strongly linked to insulin resistance and long-term cardiometabolic risk. Co-investigator Thomas Yates highlighted that GLP-1 and related drugs cause 25–45% of their weight loss from lean mass, whereas exercise preserves or builds it.
Caveats include the open-label design, the relatively short follow-up, and the highly motivated participant pool. Whether remission is sustained beyond 24 weeks and how broadly the protocol can be scaled remain open questions. Still, the findings add powerful evidence that structured lifestyle intervention can reverse — not merely manage — early type 2 diabetes, with metabolic benefits that go beyond what the scale alone measures.
Key Findings
- 54% of young adults with early-onset type 2 diabetes achieved full remission through diet and exercise alone, vs. 4% in usual care.
- An 800–900 calorie meal-replacement diet combined with three weekly exercise sessions drove remission over 12 weeks.
- The intervention reduced visceral and liver fat more than tirzepatide, despite lower total weight loss.
- Exercise preserved lean mass, avoiding the 25–45% lean-mass loss seen with GLP-1-class medications.
- 90% of participants completed the demanding protocol, demonstrating real-world feasibility.
Methodology
This is a meeting coverage news report from MedPage Today based on results presented at EASD 2026, with simultaneous publication in Lancet Regional Health Americas. The source trial is a randomized controlled trial (RESET for Remission, n=96), lending high evidentiary weight. The article is concise meeting coverage and may omit secondary endpoints and full statistical detail available in the primary publication.
Study Limitations
The trial was open-label, making blinding impossible and potentially inflating adherence via participant motivation. Follow-up was only 24 weeks, so long-term durability of remission is unknown. The study population was relatively small (n=96) and highly engaged, which may limit generalizability to less motivated or more metabolically complex patients.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: